Best VCs for Medical Devices
275 venture capitalists actively investing in Medical Devices.
Partner
Khosla Ventures
Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicin
Investor
BoxGroup
Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-dev
Partner Emeritus
Big Pi Ventures
Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and indus
Managing Director
S3 Ventures
Charlie Plauche is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in
Associate
S3 Ventures
Kevin Haley is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in busi
General Partner
S3 Ventures
Eric Engineer is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in bu
Vice President
S3 Ventures
Nicole Bentz is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in bus
Principal
S3 Ventures
Joe Curry is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in busine
Founder and Managing Partner
Boomerang Ventures
Oscar Moralez invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and p
Associate
S3 Ventures
Anthony Marfisi is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in
Co-Founder and Partner
Mutual Capital Partners
Wayne Wallace invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have s
Senior Associate
S3 Ventures
Will Omberg is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in busi
Director of Platform & Network
S3 Ventures
Kathryn Deebel is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in b
Controller
S3 Ventures
Shelley Graves is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in b
Venture Partner
Boomerang Ventures
Ariel MacTavish invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and
Vice President
The Launch Place
At the firm level, The Launch Place provides catalytic pre-seed and seed capital plus consulting to scalable technology companies willing to build operations in the Dan River region.
Partner and Chief Innovation Officer
Boomerang Ventures
Audrey Beckman invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and
Studio Director
Boomerang Ventures
Dick Aderman is listed in a Studio Director capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and
Principal, Investment Operations
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Controller and HR Lead
Boomerang Ventures
Todd R. Lugar is listed in a Controller and HR Lead capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinc
Partner and Chief Financial Officer
Boomerang Ventures
Tony Petrucciani is listed in a Partner and Chief Financial Officer capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves t
Co-Founder and Partner
Mutual Capital Partners
Bill Trainor invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have st
CFO
RC Capital
Adrienne Vannarsdall contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and
Project Leader
Boomerang Ventures
Ally Thill is listed in a Project Leader capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and us
Venture Partner
Boomerang Ventures
Dan Clark invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patie
Partner
Boomerang Ventures
David Helmer invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and pa
Partner and Chief Medical Officer
Boomerang Ventures
Eric Beier invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and pati
Associate
Boomerang Ventures
Tejas Vijh invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and pati
Principal
Mutual Capital Partners
Liz Todia Zambory invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that ha
Senior Associate
Mutual Capital Partners
Will Brune invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have stro
Partner
Clarevia
John Neis invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and dev
Partner and Chief Financial Officer
Clarevia
David Arnstein is listed in a Partner and Chief Financial Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared c
Office Manager
The Launch Place
At the firm level, The Launch Place provides catalytic pre-seed and seed capital plus consulting to scalable technology companies willing to build operations in the Dan River region.
Founding Partner
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Founding Member
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Partner
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Chief Scientific Officer
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Managing Partner, GPG Ventures - Houston
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Partner, Diagnostics
Kurma Partners
The official roster identifies Philippe Peltier as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrowe
Investment Partner
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Head of Investor Relations
GPG Ventures
At the firm level, GPG Ventures invests nationally in early-stage and growth healthcare and medical technology companies, pairing scientific and operating diligence with fund and portfolio support.
Managing Partner
RC Capital
Daniel Fleming contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and health
Managing Partner
RC Capital
J. Carter McNabb contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and heal
Managing Partner
RC Capital
Robert Heimann contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and health
Managing Partner
RC Capital
Rurik “Rik” Vandevenne contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services an
Partner
RC Capital
Patrick Dunnigan contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and heal
Founder and Managing Partner
Panakès Partners
Alessio Beverina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outco
Principal
RC Capital
Parag Rathi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcar
Principal
RC Capital
Vitaly Goldfeder contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and heal
Principal, Investor Relations & Operations
RC Capital
Britney Hamberg contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healt
Controller
RC Capital
Dana Tanenbaum contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and health
Vice President
RC Capital
Paul Axelrod contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthca
Vice President
RC Capital
Scott Steever contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthc
Vice President
RC Capital
Ryan Moeller contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthca
Senior Associate
RC Capital
Marcus Fields contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthc
Analyst, Investor Relations
RC Capital
Saloni Rai contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare
Analyst, Investments
RC Capital
Kushal Modi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcar
Analyst, Finance
RC Capital
Britney Byrd contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthca
Manager of Administration
RC Capital
Kaity Lynch contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcar
Managing Partner
Clarevia
Jim Adox invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and devi
Partner
Clarevia
Scott Button invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and
Partner
Clarevia
Paul Weiss invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and de
President and Chief Executive Officer
The Launch Place
At the firm level, The Launch Place provides catalytic pre-seed and seed capital plus consulting to scalable technology companies willing to build operations in the Dan River region.
General Partner
Boomerang Ventures
Alex Shandiz invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and pa
Chief Medical and Scientific Officer
Clarevia
Joe Amaral, MD is listed in a Chief Medical and Scientific Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared
Principal
Clarevia
Jenni Le invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and devi
Venture Partner
Clarevia
Margaret Kaczor Andrew invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therap
Executive in Residence
Clarevia
Cheryl R. Blanchard, PhD invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from ther
Venture Partner
Clarevia
Shelly Lanning invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic an
Controller
Clarevia
Becky Hoerman is listed in a Controller capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Office Manager
Clarevia
Linda Olson is listed in a Office Manager capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Partner, Diagnostics
Kurma Partners
The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower
Managing Partner, Biofund
Kurma Partners
The official roster identifies Rémi Droller as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrow
Partner, Biofund
Kurma Partners
The official roster identifies Amanda Gett as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individ
Partner, Diagnostics
Kurma Partners
The official roster identifies Alain Horvais as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower i
Managing Partner, Biofund
Kurma Partners
The official roster identifies Thierry Laugel as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narr
Partner Germany, Biofund
Kurma Partners
The official roster identifies Peter Neubeck as Partner Germany, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrow
Partner Germany, Growth Opportunities
Kurma Partners
The official roster identifies Daniel Parera as Partner Germany, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authorit
General Partner
S3 Ventures
Aaron Perman is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in bus
Partner, Growth Opportunities
Kurma Partners
The official roster identifies Jean-François Rivassou as Partner, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authori
Partner, Biofund
Kurma Partners
The official roster identifies Hadrien Bouchez as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower ind
Associate, Diagnostics
Kurma Partners
The official roster identifies Laura Achach as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower
Associate, Diagnostics
Kurma Partners
The official roster identifies Samantha Zennou as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrow
Associate, Biofund
Kurma Partners
The official roster identifies Florence de Coorebyter as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a nar
Associate, Biofund
Kurma Partners
The official roster identifies Anna Tchorzewska as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower
Associate, Growth Opportunities
Kurma Partners
The official roster identifies Maylis Deschamps as Associate, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority o
Analyst, Diagnostics
Kurma Partners
The official roster identifies Louise-Marie Rakotoarison as Analyst, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or
Secretary General, Head of Compliance & Legal
Kurma Partners
The official roster identifies Muriel Domine as Secretary General, Head of Compliance & Legal. This is a fund team or operating role; no direct investment mandate or personal signing authority is infe
Financial Director
Kurma Partners
The official roster identifies Cyril Bedran as Financial Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Senior Financial Controller
Kurma Partners
The official roster identifies Sonny Guilhem as Senior Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Financial Controller
Kurma Partners
The official roster identifies Ornella Gomis as Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Office Manager
Kurma Partners
The official roster identifies Steffi Minga as Office Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Management Assistant
Kurma Partners
The official roster identifies Fatima Boubnad as Management Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Founder and Managing Partner
Panakès Partners
Fabrizio Landi works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcome
Managing Director
S3 Ventures
Brian R. Smith is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in b
Founder and Managing Partner
Panakès Partners
Diana Saraceni works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcome
Partner
Panakès Partners
Barbara Castellano works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver out
Partner
Panakès Partners
Rob Woodman works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes.
Scientific Partner
Panakès Partners
Marco Sardina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes
Principal
Panakès Partners
Alessio Piuma works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes